Semaglutide Improves Severe Liver Disease in Phase 3 Trial
Semaglutide effectively treated the life-threatening liver disease metabolic dysfunction–associated steatohepatitis (MASH) in nearly 2 out of 3 patients, or 63%, a phase 3 clinical trial found.
Semaglutide effectively treated the life-threatening liver disease metabolic dysfunction–associated steatohepatitis (MASH) in nearly 2 out of 3 patients, or 63%, a phase 3 clinical trial found.
